Table 3.
Current vaccines in preclinical studies.
| Vaccine | Vaccine Type | Description | Author |
|---|---|---|---|
| M. tuberculosis H37Rv ΔleuD ΔpanCD strain | Live | Strain used as a TB infection model in G. mellonella | Asai, M., et al. [60] |
| H56:CAF01 | Subunit/Adjuvanted | Vaccination strategy of priming and mucosal pull immunization and analysis with uptake of H56/CAF01 | Thakur, A., et al. [46] |
| H64:CAF01 | Subunit/Adjuvanted | Protein fusion vaccine | Stockdale, L. & Fletcher, H. [13] |
| CysVac2/AdVax | Subunit/Adjuvanted | CysVac2 contains Ag85B and CysD; promotes generation of CD4+ T cells | Counoupas, C., et al. [61] |
| BCG-PSN | Subunit/Adjuvanted | BCG polysaccharide and nucleic acid injection | Yan, Q., et al. [62] |
| LT70 | Subunit/Adjuvanted | Induced humoral and cell mediated immunity and higher protective efficacy than BCG | Liu, X., et al. [63] |
| rBCG:LTAK63 | Recombinant | Subunit vaccine with LTAK63 adjuvant; lower levels of LTAK63 created stronger immune response | Carvalho Dos Santos, C., et al. [64] |
| rBCG(Δ)ais1/zmpl | Recombinant | Recombinant BCG | Yadav, J., et al. [9] |
| BCG-ZMPI | Recombinant | Recombinant live mycobacterial, lacking zmp1 gene | Stockdale, L. & Fletcher, H. [13] |
| FnBPA+ (pValac:ESAT-6) |
Recombinant | BCG booster vaccine | Pereira, V.B., et al. [65] |
| M. smegmatis expressing Ag85B | Recombinant | Recombinant bacterium study to evaluate immunogenicity | Kadir, et al. [66] |
| ChAdOx/MVA PPE15 | Recombinant | Viral recombinant | Stockdale, L. & Fletcher, H. [13] |
| CMV-6Ag | Recombinant | Contains ESAT-6, Ag85A, Ag85B, Rv3407; Rv1733; Rv2626, Rpf A, Rpf C, rpf D | Stockdale, L. & Fletcher, H. [13] |